KROS Keros Therapeutics: Company Short-Term Debts

Keros Therapeutics (KROS) is developing agents to restore hematopoiesis, targeting the massive anemia therapy market. However, a high burn rate and uncertainty regarding test outcomes pose threats to stability. The company's price chart reflects a short-term debt level of 0.00. Since the business is independent of broader economic conditions, the primary growth catalyst will be the trial results of new hematological drugs.

This indicator determines the issuer's short-term solvency by assessing its credit risk. The metric aggregates all liabilities with a maturity of up to one year. By analyzing the level of short-term debt load, an investor can see the current volume of financial obligations. For Keros Therapeutics (KROS), this is critical, as the lack of revenue coupled with rising trial costs necessitates constant external financing. The balance between debt and expansion determines the biotech's viability.